• Explore /
  • Poster
  • / Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.

Quantitative imaging by automated bone scan index (BSI) as a response biomarker in standard clinical care of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.

Abstract Poster

Authors

null

Aseem Anand

Department of Clinical Sciences Malmö Division of Urological Cancer, Lund University, Malmö, Sweden

Aseem Anand , Sarah Lindgren Belal , Mariana Reza , Lars Edenbrandt , Anders Bjartell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 288)

DOI

10.1200/jco.2015.33.7_suppl.288

Abstract #

288

Poster Bd #

E6

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium

Impact of <sup>68</sup>Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.

Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.

First Author: Amelia Altavilla

First Author: Kambiz Rahbar

First Author: Julie Nicole Graff

First Author: Ken Herrmann